Dipyridamole Induced Ischemia and Biomarkers

Completed

• Conditions: Ischemic Heart Disease; Ischemic Attack
• Interventions: Diagnostic Test: myocardial perfusion scintigraphy

• Registration Number: NCT03688815
• Lead Sponsor: University of Pecs

Brief Summary

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.

Detailed Description

The prospectively enrolled patients were followed up to 5 years. Adverse major events (MI, stroke, death) suffered during follow-up were retrospectively analysed.

Study Timeline

• Study Start: 2009-01-01
• Primary Completion: 2010-01-01
• Study Completion: 2017-01-01
• Status Verified: 2018-09
• Study First Submitted: 2018-09-25
• Study First Submitted QC: 2018-09-27
• Last Update Submitted: 2018-09-27
• Study First Posted: 2018-09-28
• Last Update Posted: 2018-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. written informed consent. 2. clinical diagnosis of ischemic heart disease (IHD) -

Exclusion Criteria

1. refused written informed consent. 2. lost data during follow-up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with ischemic heart disease	myocardial perfusion scintigraphy	Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.

Primary Outcome Measures

Name	Time	Method
Myocardial perfusion abnormality	5 year follow-up after MPS	Myocardial perfusion was quantified based on myocardial perfusion scintigraphy (MPS).

Trial Locations

Locations (1)

University of Pecs; 🇭🇺 Pécs, Baranya, Hungary